18F-FET PET可否缩小胶质母细胞瘤放疗边距:复发模式分析
本研究纳入2009年5月至2014年11月间36例原发放化疗前接受18F-FET PET检查的胶质母细胞瘤患者,将生物肿瘤体积与MR-based GTV融合,分析复发模式并评估包含所有复发部位所需最小边距。结果显示PET-MRGTV所需最小边距显著小于MRGTV(中位12.5 mm vs 16.5 mm,p<0.001),提示18F-FET PET可能有助于缩小CTV边距。
要点
- PET-MRGTV包含全部复发强化灶的最小边距显著小于MRGTV(12.5 mm vs 16.5 mm)。
- PET-MRGTV 15 mm CTV边距体积显著小于MRGTV 20 mm CTV边距。
- 两者复发模式可比,PET-MRGTV 15 mm组无边缘复发。
核心结论
- 18F-FET PET可更准确检测活性肿瘤,改善GBM靶区勾画,并提示原发放疗前PET成像可能缩小CTV边距。
研究设计与样本
- 回顾性复发模式分析,纳入2009年5月至2014年11月原发放化疗前接受18F-FET PET检查的36例GBM患者。
主要发现
- PET-MRGTV包含全部复发强化灶的最小边距中位12.5 mm,显著小于MRGTV的16.5 mm(p<0.001,Wilcoxon检验)。
- PET-MRGTV 15 mm CTV边距体积中位255.92 cm3,显著小于MRGTV 20 mm CTV边距的258.35 cm3(p=0.020,Wilcoxon检验,排除3例大体积非强化肿瘤)。
- PET-MRGTV 15 mm组与MRGTV 20 mm组复发模式可比:中央复发32 vs 30例,野内2 vs 4例,野外2 vs 2例,均无边缘复发。
关键数值与推荐
- 包含全部复发强化灶的最小边距:PET-MRGTV中位12.5 mm,MRGTV中位16.5 mm(p<0.001)。
- PET-MRGTV 15 mm CTV与MRGTV 20 mm CTV体积比较:255.92 vs 258.35 cm3(p=0.020)。
临床怎么用
- 原发放疗前18F-FET PET联合增强MRI可用于改善GBM靶区勾画。
- 基于PET的靶区可能安全缩小CTV边距至15 mm,但需进一步验证。
局限性
- 样本量36例,为单中心回顾性分析。
- 体积比较排除3例大体积非强化肿瘤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: 18F-fluoroethyltyrosine (18F-FET) PET is increasingly used in radiation treatment planning for the primary treatment of glioblastoma (GBM) patients additionally to contrast-enhanced MRI. To answer the question, whether a margin reduction in the primary treatment setting could be achieved through 18F-FET PET imaging, a recurrence pattern analysis was performed. PATIENTS AND METHODS: GBM patients undergoing 18F-FET PET examination before primary radiochemotherapy from 05/2009 to 11/2014 were included into the recurrence pattern analysis. Biological tumour volumes were semi-automatically created and fused with MR-based gross tumour volumes (MRGTVs). The pattern of recurrence was examined for MRGTVs and for PET-MRGTVs. The minimal margin including all recurrent tumour sites was assessed by gradual expansion of the PET-MRGTVs and MRGTVs until inclusion of all contrast-enhancing areas at recurrence. RESULTS: 36 GBM patients were included to the analysis. The minimal margin including all contrast enhancing tumour at recurrence was significantly smaller for the PET-MRGTVs compared to the MRGTVs (median 12.5 mm vs. 16.5 mm; p < 0.001, Wilcoxon-Test). PET-MRGTVs with 15 mm CTV margins were significantly smaller than MRGTVs with 20 mm CTV margins (median volume 255.92 vs. 258.35 cm3; p = 0.020, Wilcoxon-Test; excluding 3 cases with large non-contrast enhancing tumours). The pattern of recurrence of PET-MRGTVs with 15 mm CTV margins was comparable to MRGTVs with 20 mm CTV margins (32 vs. 30 central, 2 vs. 4 in-field, 2 vs. 2 ex-field and no marginal recurrences). CONCLUSION: Target volume delineation of GBM patients can be improved through 18F-FET PET imaging prior to primary radiation treatment, since vital tumour can be detected more accurately. Furthermore, the results suggest that CTV margins could be reduced through 18F-FET PET imaging prior to primary RT of GBM.
引用
- Fleischmann DF, Unterrainer M, Schön R, et al. Margin reduction in radiotherapy for glioblastoma through 18F-fluoroethyltyrosine PET? - A recurrence pattern analysis. Radiother Oncol. 2020. PMID: 31923709. doi:10.1016/j.radonc.2019.12.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。